Limited Time Offer: 20% Discount on GlobalData Report Covering Atopic Dermatitis Market Available at MarketPublishers.com
17 Mar 2014 • by Natalie Aster
LONDON – There are still high rates of unmet medical need within atopic dermatitis (AD) for a better therapeutic armamentarium for recalcitrant patients. The latter remain underserved as physicians often lack pharmacological options following treatment failure with cyclosporine, or intolerance to the drug, which often results in AD therapies being prescribed off-label. Although cyclosporine is indicated for the short-term treatment of AD in some countries of Europe, key-note dermatologists believe there is no true drug used systemically for AD patients. Having the most clinically advanced systemic drug in AD pipeline, Sanofi SA and Regeneron Pharmaceuticals Inc are best-positioned to address this hugest and most urgent unmet need within patients with moderate to severe AD, and are poised to set a precedent with their novel blockbuster pipeline candidate – dupilumab. Moreover, their first biologic will most likely prepare the ground for others to follow suit. The noticeable excitement over dupilumab arises from its novelty as an interleukin-4receptor alpha (IL-4Ralpha) inhibitor and its initial positive results of early-phase clinical trials.
The AD therapeutic sales in the 9 major markets (9MM) are forecast to increase at a CAGR of around 4% and reach USD 5.6 billion by 2022-end.
Discounted report “PharmaPoint: Atopic Dermatitis - Global Drug Forecast and Market Analysis to 2022” worked out by GlobalData presents an overview of AD (including epidemiology, pathophysiology, etiology, symptoms, diagnosis, and today’s treatment options); covers annualized AD therapeutics market revenue, annual cost of AD therapy and treatment use pattern data (from 2012 with forecasts to 2022). The study provides market characterization, a strategic competitor analysis, limelights unmet needs, and implications for the AD therapeutics markets. A detailed pipeline analysis is included, comprising exhaustive data split across different clinical phases, emerging new trends under development, and an analysis of pipeline drugs in mid- to late-stage clinical development. The report assesses the competition (as of today and in the offing) in the global AD therapeutics markets. A deep analysis of industry challenges, restraints & drivers is provided, too.
Companies covered are: Astella, Meda, Regeneron, and Anacor.
PharmaPoint: Atopic Dermatitis - Global Drug Forecast and Market Analysis to 2022
Published: November, 2013
Price: US$ 9,995.00 US$ 7,996.00
The special discount offer ends March 28th 2014!
More reports by the publisher can be found at GlobalData page.